Keeping Up with FDA and DOH Regulations

Level: Advanced
Runtime: 60 minutes
Recorded Date: September 25, 2019
Click here to share this program
Download PDF


  • Guidance Documents
  • Medical Device Development Tools (MDDT)
  • Digital Health Initiative
  • 21st Century Cures
  • Smart Regulation Principles for Digital Health Tech
Runtime: 1 hour
Recorded: September 25, 2019


Pharmaceutical and biotechnology companies are heavily regulated to ensure compliance with federal safety laws for use and consumption. The US FDA oversees regulatory activity across the globe, forcing pharma & life sciences companies to identify quality issues before they impact the production. The FDA also has the authority to inspect manufacturers and facilities that are registered, including compound pharmacies, to ensure compliance with safety ordinances. Additionally, life science corporations must also comply with state-regulated laws implemented by each respective state’s DOH. So with all of these laws and regulations in effect, how does one ensure compliance across the board?

This panel will explore what GCs need to know to effectively advise their organizations on operations standards and compliance risks.

This program was recorded as part of ALM & Corporate Counsel's Annual General Counsel Conference on September 25th, 2019.

Provided By

General Counsel Conference


Gina Mazzariello

Vice President
Boehringer Ingelheim Pharmaceuticals, Inc.

Gina Mazzariello is the Vice President of US Human Pharma Business Law at Boehringer Ingelheim Pharmaceuticals, Inc.

Shawn Gibbs

Associate General Counsel

Shawn Gibbs is the Associate General Counsel at Seqirus.

Similar Courses

Card image cap
92 minutes
#MeToo: Empowering Employees and Employers to Address Workplace Sexual Harassment & Violence
Join our expert attorneys as they discuss how employers can work to prevent and eliminate sexual harassment and violence in their workplace, and create an environment in which employees are able to respond to and report incidents without fear of retaliation. Not only is there a deep moral imperative to rectify sexual harassment in the workplace and promote an equitable work environment, but also there is significant monetary liability as a potential consequence for employers who fail to address harassment in the workplace.

American Bar Association


Add to Cart
Card image cap
77 minutes
§ 363 Sale Issues
Dive into Section 363 sales issues, including whether there are limits to “free and clear”; the GM conflict between Sections 365(h) and 363(f) (“lease-stripping”); sales free and clear of leasehold interests, restrictive covenants and override royalties; being free and clear of successorships in CBAs; selling free and clear of environmental liabilities (La Paloma, Exide); and loan-to-own strategies.

American Bankruptcy Institute


Add to Cart
Card image cap
63 minutes
2018 CA Consumer Privacy Act: The Big Tail Wagging the U.S.
In this session, two leading information governance attorneys will share why you need to and how you can be ready.



Add to Cart
Card image cap
60 minutes
2019 HIPAA Update: Enforcing Privacy & Security Standards
In this session, we will discuss the most critical issues in the HIPAA update and best practices for enforcing privacy & security standards in your company.



Add to Cart
Previous Next